ClinicalTrials.gg
RecruitingNCT06024421FAVIDOSEUpdated Feb 12, 2026

Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

A Phase 1 interventional study of favipiravir and Placebo in Infectious Disease and Pharmacology, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Communicable Diseases with a site in France — 16 open to participants now, 16 under way, 2 of them phase 3. Communicable Diseases · France.

Planned enrollment
9th of 11
39 · median 75
Started
2024
with 3 others
Phase 1
Only one
of the 42
Primary completion
2027-06
later than 4 of 15 live
Registered
28th of 42
by date
Lead sponsor
4 of 42
Institut National de la Santé Et de la Recherche Médicale, France

Among the 42 studies in Communicable Diseases with a site in France, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2024, is the only one in phase 1, reaches primary completion later than 4 of the 15 other live ones, and was the 28th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

16 of the 42 studies in Communicable Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Communicable Diseases with a site in France, or all of them as a file.
02

Study summary

FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir for 14 days in healthy volunteers. This trial also looks to characterize favipiravir pharmacokinetics in blood and favipiravir levels in sperm. A pharmacogenetics analysis will be conducted in an attempt to identify genetic variants of metabolism and transport enzymes of favipiravir to explain the inter-individual variability of pharmacokinetic parameters of favipiravir.

Three sequential dose levels including distinctive participants:

  • level 1: D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning;
  • level 2: D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning;
  • level 3: D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning.

Three study groups of maximum of 8 participants, 6 receiving favipiravir and 2 receiving placebo per dose level, three dose levels proposed. Seven additional participants with the same follow up will be included and randomized (6:1 ratio) at the maximum tolerated dose level to allow a satisfactory accurate characterization of pharmacokinetics and pharmacogenetics of favipiravir and their determinants (maximum 39 participants in total, taking into account 8 participants - 2 per dose level - replaced because loss of follow-up before the end of treatment).

03

Conditions studied

  • Infectious Disease
  • Pharmacology

Browse trials for

Keywords

  • healthy volunteer
  • dose escalation
  • tolerance
  • pharmacokinetics
  • favipiravir
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Man between 50 and 75 years old without any desire to have children or woman between 18 and 75 years old ;
  2. Subject considered healthy after a thorough general examination (questioning, physical examination);
  3. For men: acceptance of semen collection by masturbation;
  4. For men: acceptance of condom use from initiation of the drug until 1 month after stopping the investigational drug;
  5. For women of : effective method combining two methods of contraception (one female contraceptive method combined with male condom use) from the inclusion visit until 1 month after discontinuation of the investigational drug;
  6. Blood chemistry:

    • Kalemia, Calcemia, Prothrombin rate (PT), (APTT): values within laboratory normal;
    • , ASAT, Uricemia: values below the upper limit of the laboratory normal;
    • Other biological results (Blood count; Natremia; Phosphoremia; Chloremia; Fasting blood glucose; Gamma glutamyl transpeptidase; Urea; Total ; Creatinine; CPK; Lactate dehydrogenase; Albuminemia; Proteinemia; Triglycerides; C-reactive protein; Albumin/Globulin ratio; Alkaline phosphatase) with no abnormality.

    NB: A parameter outside the usual values considered clinically significant may, at the investigator's discretion, be tested a second time on another sample taken outside of a visit planned in the protocol before the initiation of the experimental drug.

  7. Urine dipstick (biochemistry: leukocyturia, proteinuria and hematuria) without clinically significant abnormality;
  8. Urine tox screen negative (amphetamines/metamphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates);
  9. Ability to take the investigational drug orally and adherence to the dosage of the investigational drug;
  10. Acceptance and signing of the ;
  11. Membership in a social security plan or beneficiary of such a plan;
  12. Adherence to lifestyle considerations (see section 5.5) during participation in this research.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant use or within 15 days prior to inclusion of another /QTc prolonging drug or drugs that may disrupt electrolyte levels, among others: loop diuretics, thiazide diuretics and related drugs (see list www.crediblemeds.org)
  2. History of amiodarone use within 6 months prior to inclusion
  3. History of gout or current treatment for gout or hyperuricemia
  4. Treatment with pyrazinamide or any other drug known to induce hyperuricemia
  5. History of reaction to a nucleoside analog targeting viral RNA polymerase
  6. Known hypersensitivity to any of the components (favipiravir or placebo)
  7. Pregnant or breastfeeding women
  8. For men: history of vasectomy or known history of infertility.
  9. Refusal of the subject to complete all the visits, clinical and paraclinical examinations planned by the study
  10. On : PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization
  11. PAS \<100 mmHg
  12. Any history or active cardiovascular, pulmonary, intestinal, hepatic, renal, metabolic, hematologic, neurologic, bone, joint, muscular, psychiatric, systemic, ocular, gynecologic, andrologic, or infectious disease (including active , , or infection), or any acute condition, which in the judgment of the investigator could be detrimental to the volunteer and/or interfere with or limit the protocol evaluation and data analysis
  13. Personal or family history of long QT syndrome, torsades de pointes or sudden death
  14. Patient with severe hepatic impairment
  15. Gastrointestinal pathology such as ileus, colitis or enterocolitis
  16. Treatment with another drug or other investigational procedure (clinical trial, clinical investigation of a medical device, category 1 or 2 research involving humans);
  17. A person who is subject to a legal protection measure (safeguard of justice, curatorship, guardianship);
  18. Person placed in administrative detention;
  19. Person who, in the judgment of the investigating physician, may be non-observant during the study, or unable to communicate due to a language barrier or mental disorder
  20. Person who cannot be contacted in an emergency
  21. Person with at least one first-degree relative from East Asia or Southeast Asia.

Secondary Exclusion Criteria

Participants with at least one of the following criteria will not start the experimental treatment at D1 if they are already randomized:

  1. Positive nasopharyngeal antigen test for SARS-CoV-2 at D1 (prior to treatment initiation)
  2. Blood potassium levels outside the normal laboratory range within 8 days prior to treatment initiation (D1)
  3. ECG: PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization on Day 1
  4. Positive pregnancy test on Day 1 (before initiation of treatment)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    level 1: experimental

    D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning

    Drug: favipiravir

  • Experimental
    level 2: experimental

    D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning

    Drug: favipiravir

  • Experimental
    level 3: experimental

    D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning

    Drug: favipiravir

  • Placebo comparator
    level 1: placebo

    D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning

    Drug: Placebo

  • Placebo comparator
    level 2: placebo

    D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning

    Drug: Placebo

  • Placebo comparator
    level 3: placebo

    D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning

    Drug: Placebo

Interventions

  • Light yellow, film-coated tablet, each containing 200 mg of favipiravir

  • DrugPlacebo

    Light yellow, film-coated tablet

06

What researchers measure

Primary outcomes

  1. Tolerance

    Tolerance of high doses of favipiravir, defined by the number of participants with at least one adverse medical event considered as related to favipiravir (AER)-as determined and validated by the sponsor- clinical stage 3 or 4 according to the CTCAE (v5.0) not found at inclusion at same level and biological AER de stage 3 or 4 not found at inclusion in the same level. AER are collected daily until D15 and at D21 and D28, as well as at M3 and M6 for participating men. D1 is the first day of favipiravir or placebo intake.

    Time frame: Months 6

Secondary outcomes

  1. Plasma concentration of favipiravir

    Construction of the pharmacokinetic model and the estimation of its parameters will be realized by a population pharmacokinetic analysis integrating all available data on plasma concentration.

    Time frame: Day 1 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 3 (Hour 0 ; Hour 0.5; Hour 2), Day 7 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 10 (Hour 0), Day 14 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 15 (Hour 0)

  2. Genetic

    Genetic variants associated with favipiravir exposure. Targeted genotyping of variants of the gene encoding the enzyme responsible for transport and metabolism of favipiravir (aldehyde deshydrogenase) will be performed.

    Time frame: Days 1

  3. Sperm pharmacology

    For participating men: favipiravir concentration in sperm at D14 and D28.

    Time frame: Day 14, day 28

07

Study locations

1 of 1 sites recruiting
  • University Hospital Bichat - Claude Bernard
    Paris, 75018, France
    Recruiting
    • Xavier Duval · Contact
    • Xavier Duval · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2027, 37 months after the start.

Of 25 phase 1 interventional studies under Communicable Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Sep 6, 2023
StartActual
May 14, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Nov 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06024421
Collaborators
FUJIFILM Toyama Chemical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
May 14, 2024
Primary completion
Jun 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Cedric LAOUNAN
Contact
cedric.laouenan@inserm.fr
+33 1 40 25 79 31
Philippine ELOY
Contact
philippine.eloy@aphp.fr
+33 1 40 25 79 31
Denis MALVY
study chair · CHU de Bordeaux & INSERM, Université de Bordeaux, France
Xavier DUVAL
principal investigator · APHP Hôpital Bichat Claude Bernard
Jean-Jacques KILADJIAN
study director · INSERM Pôle Recherche Clinique

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Favipiravir

Start the discussion